Spero Therapeutics Stock Price, News & Analysis (NASDAQ:SPRO) $1.27 -0.02 (-1.55%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$1.21▼$1.3150-Day Range$1.00▼$1.2952-Week Range$0.99▼$2.04Volume155,056 shsAverage Volume357,771 shsMarket Capitalization$67.31 millionP/E Ratio127.00Dividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Spero Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside451.2% Upside$7.00 Price TargetShort InterestHealthy2.13% of Shares Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$50,160 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.50) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector256th out of 957 stocksBiotechnology Industry12th out of 67 stocks 3.5 Analyst's Opinion Consensus RatingSpero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Spero Therapeutics has a forecasted upside of 451.2% from its current price of $1.27.Amount of Analyst CoverageSpero Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.13% of the outstanding shares of Spero Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Spero Therapeutics has recently decreased by 10.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpero Therapeutics has received a 74.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Spero Therapeutics is -0.80. Previous Next 0.6 News and Social Media Coverage Search Interest5 people have searched for SPRO on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,160.00 in company stock.Percentage Held by InsidersOnly 4.21% of the stock of Spero Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 27.25% of the stock of Spero Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spero Therapeutics are expected to decrease in the coming year, from ($0.50) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is 127.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 116.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is 127.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 106.64.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Spero Therapeutics Stock (NASDAQ:SPRO)Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More SPRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRO Stock News HeadlinesNovember 28, 2023 | americanbankingnews.comSpero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below Two Hundred Day Moving Average of $1.39November 14, 2023 | finance.yahoo.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call TranscriptDecember 7, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business UpdateNovember 13, 2023 | benzinga.comRecap: Spero Therapeutics Q3 EarningsNovember 13, 2023 | finance.yahoo.comSpero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business UpdateNovember 12, 2023 | msn.comSpero Therapeutics Q3 2023 Earnings PreviewNovember 12, 2023 | markets.businessinsider.comHere's what Wall Street expects from Spero Therapeutics's earnings reportDecember 7, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 6, 2023 | finance.yahoo.comSpero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023November 2, 2023 | businesswire.comSPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmNovember 1, 2023 | finance.yahoo.comSpero Therapeutics to Present at Upcoming November Investor ConferencesNovember 1, 2023 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business OfficerOctober 18, 2023 | finance.yahoo.comAll You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to BuySeptember 20, 2023 | finance.yahoo.comSpero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor ConferenceSeptember 16, 2023 | finance.yahoo.comInsider Sell: Chief Medical Officer Kamal Hamed Sells 39,496 Shares of Spero Therapeutics IncSeptember 6, 2023 | finance.yahoo.comSpero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 5, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Spero TherapeuticsAugust 31, 2023 | msn.comSpero Therapeutics (SPRO) Price Target Increased by 5.26% to 6.80August 29, 2023 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?August 22, 2023 | finance.yahoo.comDown -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a TurnaroundAugust 16, 2023 | nasdaq.comAlaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%August 14, 2023 | msn.comHC Wainwright & Co. Maintains Spero Therapeutics (SPRO) Buy RecommendationAugust 14, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Spero Therapeutics: Here's What You Need To KnowAugust 13, 2023 | finance.yahoo.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call TranscriptAugust 11, 2023 | finance.yahoo.comQ2 2023 Spero Therapeutics Inc Earnings CallAugust 10, 2023 | finance.yahoo.comSpero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business UpdateSee More Headlines Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRO CUSIPN/A CIK1701108 Websperotherapeutics.com Phone(857) 242-1600FaxN/AEmployees35Year Founded2013Price Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+451.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio127.00 Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,420,000.00 Net Margins-2.08% Pretax Margin0.77% Return on Equity4.14% Return on Assets2.33% Debt Debt-to-Equity RatioN/A Current Ratio4.01 Quick Ratio4.01 Sales & Book Value Annual Sales$53.51 million Price / Sales1.26 Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book0.88Miscellaneous Outstanding Shares53,000,000Free Float50,768,000Market Cap$67.31 million OptionableOptionable Beta0.86 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Ankit Mahadevia M.D. (Age 42)MBA, Co-Founder & Chairman of the Board Comp: $1.24MMr. Satyavrat Shukla C.F.A. (Age 51)President, CEO & Director Comp: $823.27kMs. Tamara Lynn Joseph L.L.M. (Age 60)Chief Legal Officer Comp: $775.55kMs. Esther P. Rajavelu (Age 44)CFO & Chief Business Officer Mr. Timothy Keutzer (Age 55)Chief Operating Officer Ted JenkinsVP & Head of Investor RelationsMr. James P. BradyChief Human Resource OfficerDr. Kamal Hamed M.B.A. (Age 62)M.D., M.P.H., Chief Medical Officer More ExecutivesKey CompetitorsTrevi TherapeuticsNASDAQ:TRVICheckpoint TherapeuticsNASDAQ:CKPTClearside BiomedicalNASDAQ:CLSDLeap TherapeuticsNASDAQ:LPTXBioVieNASDAQ:BIVIView All CompetitorsInsiders & InstitutionsRock Springs Capital Management LPSold 612,160 shares on 11/15/2023Ownership: 0.109%AWM Investment Company Inc.Sold 50,000 shares on 11/14/2023Ownership: 0.632%Acadian Asset Management LLCBought 98,485 shares on 11/13/2023Ownership: 0.516%Group One Trading L.P.Sold 60,000 shares on 11/9/2023Ownership: 0.000%Kamal HamedSold 39,496 sharesTotal: $50,159.92 ($1.27/share)View All Insider TransactionsView All Institutional Transactions SPRO Stock Analysis - Frequently Asked Questions Should I buy or sell Spero Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares. View SPRO analyst ratings or view top-rated stocks. What is Spero Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued 12 month price targets for Spero Therapeutics' shares. Their SPRO share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 451.2% from the stock's current price. View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts. How have SPRO shares performed in 2023? Spero Therapeutics' stock was trading at $1.73 at the beginning of 2023. Since then, SPRO stock has decreased by 26.6% and is now trading at $1.27. View the best growth stocks for 2023 here. When is Spero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our SPRO earnings forecast. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics, Inc. (NASDAQ:SPRO) released its earnings results on Monday, November, 13th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.17. The company earned $25.47 million during the quarter, compared to analysts' expectations of $2.40 million. Spero Therapeutics had a positive trailing twelve-month return on equity of 4.14% and a negative net margin of 2.08%. What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO? 27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN). When did Spero Therapeutics IPO? (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Spero Therapeutics' major shareholders? Spero Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (0.63%), Acadian Asset Management LLC (0.52%), Group One Trading L.P. (0.00%), Rock Springs Capital Management LP (0.11%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin, Kamal Hamed, Sath Shukla and Timothy Keutzer. View institutional ownership trends. How do I buy shares of Spero Therapeutics? Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SPRO) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.